Last reviewed · How we verify
AV2
AV2 is a small molecule that targets the SGLT2 receptor.
AV2 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | AV2 |
|---|---|
| Also known as | Antivirus 2 |
| Sponsor | Jean-Pierre Van geertruyden |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
AV2 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB)
- Efficacy and Safety of Micra AV2 Transcatheter Pacing System (NA)
- Home-based Transcranial Direct Current Stimulation (tDCS) Compared to Duloxetine: Non-inferiority Clinical Trial (FIBROSTIM) (NA)
- A Study to Assess the Efficacy of Omnivirol-Salicylic Acid Combination Therapy for Cutaneous Warts With Emphasis on Persistent Warts (PHASE2, PHASE3)
- Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix (PHASE3)
- AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections (PHASE2)
- Changes in Invitro and ex Vivo Lens Metrology With Daily Wear Contact Lenses (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AV2 CI brief — competitive landscape report
- AV2 updates RSS · CI watch RSS
- Jean-Pierre Van geertruyden portfolio CI